stockportfolio.pro
Regencell Bioscience Holdings Limited (RGC)
Healthcare · Drug Manufacturers - Specialty & Generic · NasdaqCM
Regencell Bioscience Holdings Limited revenue & earnings — last 4 fiscal years
| Metric | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — |
| Net income | $-1.35M | $-7.45M | $-5.87M | $-4.30M |
| Net margin | — | — | — | — |
Source: Regencell Bioscience Holdings Limited SEC filings (10-K).
Explore 4 years of Regencell Bioscience Holdings Limited financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track RGC in your portfolio →
Regencell Bioscience Holdings Limited financial history by metric
About Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Regencell Bioscience Holdings Limited — frequently asked questions
What is Regencell Bioscience Holdings Limited's revenue?
Regencell Bioscience Holdings Limited (RGC) reported revenue of $0 for fiscal year 2024, according to its SEC filings.
Is Regencell Bioscience Holdings Limited profitable?
No — RGC reported a net loss of $-4.30M in fiscal 2024.
What is RGC's P/E ratio?
Regencell Bioscience Holdings Limited trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Regencell Bioscience Holdings Limited have?
As of fiscal year 2024, RGC carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Regencell Bioscience Holdings Limited's market cap?
Regencell Bioscience Holdings Limited (RGC) has a market capitalization of about $9.30B, based on the latest data in our nightly-refreshed cache.
When does Regencell Bioscience Holdings Limited's fiscal year end?
RGC's fiscal year ends in June. Its most recent annual filing covers the fiscal year ending 2024-06-30.
Where does this data come from?
All figures are computed from Regencell Bioscience Holdings Limited's official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.